<DOC>
	<DOC>NCT01020786</DOC>
	<brief_summary>To investigate efficacy and safety of the combination with pemetrexed plus carboplatin, followed by pemetrexed in patients with advanced nonsquamous Non Small Cell Lung Cancer (NSCLC) who receive at least one dose of the induction therapy.</brief_summary>
	<brief_title>A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Nonsquamous cell Non Small Cell Lung Cancer (NSCLC) disease Clinical stage IIIB/IV or recurrent disease after surgery No prior systemic chemotherapy, immunotherapy, targeted therapy or biological therapy, including adjuvant therapy Prior radiation therapy is allowed to less than 25% of the bone marrow Measurable disease as defined by response evaluation criteria in solid tumors (RECIST) The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Adequate organ function Estimated life expectancy of at least 12 weeks Clinically significant thirdspace fluid collections Central nervous system disease other than stable and treated brain metastasis More than 3 weeks interval between the surgery and enrollment request date Unable to interrupt aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs), for a 5 days period Unable or unwilling to take folic acid or vitamin B12 supplementation Unable to take corticosteroids. Serious concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol Currently have and historically had interstitial pneumonitis (interstitial pneumonia) or pulmonary fibrosis manifested as opacity on Chest xray or Computed tomography (CT)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-squamous</keyword>
</DOC>